Aspirin Resistance in Trinidad. (NCT06228820) | Clinical Trial Compass
CompletedPhase 2
Aspirin Resistance in Trinidad.
Trinidad and Tobago48 participantsStarted 2024-01-15
Plain-language summary
Aspirin's beneficial effect is mediated via the inhibition of arachidonic acid (AA) activation of platelets. It is detected by demonstrating a decrease in platelet function and/or a decrease in prostaglandin metabolites. Besides inhibiting the formation of thromboxane A2 from arachidonic acid, Aspirin has a host of platelet-independent effects that complement its platelet-inhibitory effects.
The phenomenon of "Aspirin resistance" is based on the observation of clinical events in some patients taking Aspirin and/or a diminished platelet aggregation inhibitory response to Aspirin therapy. It has been suggested that many individuals taking Aspirin have become resistant to this drug. Unfortunately, laboratory assays used to monitor the efficacy of Aspirin are far from accurate, and the results are not reproducible. Multiple studies demonstrate non-compliance using repeat testing for platelet inhibition in patients with an initial inadequate response to Aspirin. When the test is repeated under the condition that the ingestion of the test Aspirin is assured, the patients' platelets are inhibited. Patients with an inadequate Aspirin response have an increased likelihood of subsequent vascular events.
Who can participate
Age range18 Years – 74 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. between 18 and 74 years of age,
✓. healthy with no overt medical conditions,
✓. not on any physician-prescribed medications or complementary/alternative therapies,
Exclusion criteria
✕. presence of active internal bleeding or history of bleeding diathesis or clinical findings associated with an increased risk of bleeding,
✕. history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial neoplasm, arteriovenous malformation, or aneurysm,
✕. clinical and/or hemodynamic instability,
✕. within 1 month of placement of a bare metal stent,
✕. within 30 days of coronary artery bypass graft surgery or PCI without a stent placed,
✕. planned coronary revascularization,
✕. treatment with fibrin-specific fibrinolytic therapy \<24 h or non-fibrin-specific fibrinolytic therapy \<48 h,